Association Europenne

des Spcialits Pharma-

ceutiques Grand Public
Association of the European
Self-Medication Industry
Europischer Verband der
Arzneimittel-Hersteller
1964-2014
5
years
2 aesgp.eu
Table of contents
Message from the President 3
Message from the Director General 4
History 5
Mission 12
Policy recommendations 13
AESGP Members 14
How AESGP works 16
Stakeholder collaboration 18
Publications 20
Annual Meetings 24
Past Presidents and Directors General 26
AESGP Euro OTC News 27
50 Years AESGP 3
Message from the President
The year 2014 is an important milestone in the history of the Association
of the European Self-Medication Industry (AESGP); its 50th anniversary.
Initiated in the early 1960s by just three companies, the association has
grown to become the official voice of the consumer healthcare industry in
Europe. It represents national associations and directly or indirectly - through
the national associations - more than 2000 companies producing non-
prescription medicines, food supplements and self-care medical devices
AESGP celebrates its 50th anniversary having achieved the key objectives
set at the time of its establishment:
There is a recognised and established distinction between prescription
and no-prescription medicines across Europe
Communication with citizens and the provision of information through
advertising are allowed
Free pricing for manufacturers is the standard practice in nearly
all European countries, with European Union policy initiatives
unequivocally acknowledging that free pricing for manufacturers allows
the development of a competitive market environment, rendering price
control measures for non-prescription medicines unnecessary.
The realisation of the full potential of self-care will only be possible when
European citizens are empowered and well informed about different
products and their appropriate use. In the years to come, ensuring the right
of all European citizens to self-care and have access to information and
innovative, effective, safe and high quality products will remain a guiding
principle for AESGP. As before, the association will pursue this objective
highly committed, with responsibility and integrity.
Hans Regenauer, AESGP President
4 aesgp.eu
Message from the Director General
AESGP has dedicated the past 50 years to advancing the practice of self-
care in Europe. Throughout this time, the association strives to pursue its
objectives by remaining faithful to the fundamental principles of professional
competence and comprehensive service to members.
In its work, AESGP relies on the close cooperation with European authorities
and other stakeholders. It is critical that European bodies have a good
understanding of the sectors specificities and a grasp on the actual impact
of different decisions made on the self-care market. Close relationship
with different stakeholder groups has been one of the most valuable and
rewarding aspects of the associations work. Gaining a good understanding
of the interests and concerns of others has allowed AESGP to reassess
its own positioning on different issues and to work together with other
stakeholders to achieve common goals.
The same principle applies in our internal work with our members. The well
organised network of associations and companies is the driving force of
the association. It allows us to comprehensively assess the environment,
reflect on developments and take informed political decisions. The
close collaboration of the AESGP membership is the cornerstone of the
associations success and where we can attribute the significant, tangible
results for the entire consumer healthcare sector achieved through our
political work on a national, European and global level.
Hubertus Cranz, AESGP Director General
50 Years AESGP 5
History
Establishment
In 1963, a small group of representatives,
primarily from the companies Miles,
Nicholas and Vick, came together under
the Chairmanship of Ben McClure of Vick
International to discuss the possible need
for collective action in light of the many
threats and opportunities for the self-care
industry, which was then referred to as the
Proprietary Medicines Industry.
A year later, on 3 February 1964, the
Association Europenne des Spcialits
Pharmaceutiques Grand Public, AESGP was
founded in Paris.
Vision
At a time when self-care was considered to
be either synonymous with home remedies
or potentially unnecessary due to the
expected advancements of the medical
profession, the founders of the Association
envisioned a strong self medication sector:
A dynamic and innovative part of the
pharmaceutical industry that would support
increasingly empowered citizens to self-
care.
Restaurant bill from the inaugural meeting
of the AESGP founders.
1961 1962 1963 1964
6 aesgp.eu
1965 1966 1967 1968 1969 1970 1971 1972 1973 1974 1975 1976 1977
In the early years following
its establishment, AESGP
became the key liaison
between the self-care
industry and the European
Community bodies.
The growth of the sector in
Europe was supported by
AESGP, that was steadily
developing in terms of
membership and increased
involvement in the European
healthcare dialogue.
Directive 65/65/EEC
First European piece of legislation for
pharmaceuticals. It provided the definition
of a medicinal product, introduced the
requirement for an authorisation prior to
commercialisation and set out labeling
provisions.
By 1967 AESGP numbered 9
national member associations
and represented more than 300
companies.
Committee for Proprietary Medicinal
Products set up to facilitate the principle
of mutual recognition of marketing
authorisations.
Testing requirements introduced.
AESGP, together with the Associations
from the United States and Canada,
was one of the founding members, in
April 1970, of the World Federation of
Proprietary Medicines Manufacturers
(WFPMM) that would later on become
WSMI.
Reclassifications in Europe 1976: Antihistamines
50 Years AESGP 7
In the late 70s and early 80s the critical
role individuals could and should play in
maintaining their health was starting to be
recognised and supported.
WHO - Declaration of Alma-Ata
() people have the right and duty to
participate individually and collectively in
the planning and implementation of their
healthcare
WHO, International Conference on
Primary Health Care, Alma-Ata, April 1978
1978 1979 1980 1981 1982 1983 1984 1985 1986 1987 1988 1989 1990
AESGP obtains the status of non-
governmental organisation with
the Council of Europe.
AESGP Annual Meeting at the premises
of the World Health Organisation in
Copenhagen 1986
1981: Benzoyl peroxide 1983: Ibuprofen, Loperamide 1986: Hydrocortizone 1988: Nicotine
8 aesgp.eu
1991 1992 1993 1994 1995
The 90s were marked by
significant developments and
political divisions of the past
giving their place to a united
continent facing future with
the promise of progress.
Important changes were also
observed in the European
regulatory framework on
pharmaceuticals, with a
recognition of the role of non-
prescription medicines.
Reclassifications in Europe 1993: Aciclovir 1995: Fluconazole
New legislation addressing:
The classification status of medicinal
products, distinguishing between
prescription and non-prescription
medicines
Advertising, allowing the advertising
of non-prescription medicines to the
public
Patient information (labelling and
package leaflets)
Wholesale distribution
Homeopathic medicines
AESGP implements a proactive policy
for the development of a distinct
non-prescription medicines sector in
Eastern European countries.
Related activities are supported by
the publication of the policy document
Developing Self-Medication in
Central and Eastern Europe in
Russian, Bulgarian, Czech, Hungarian,
Polish and Ukrainian.
The European Medicines Agency
is established, and the centralised
procedure for the authorisation and
supervision of medicinal products
comes into operation.
50 Years AESGP 9
1996 1997 1998 1999 2000 2001
AESGP and European doctors
associations produce with the support
of the European Commission the
information document on What is
self-medication (see more under
Stakeholder collaboration, p.18).
AESGP Food Supplements
Committee established
2001/83/EC
Consolidation of the European
pharmaceutical legislation
proposed.
AESGP conducts study to improve patient
information leaflets in order to make them
more readable and useful to patients following
request by the European Commission.
AESGP conducts study on herbal
medicines commissioned by the European
Commission leading to the foundation of
Directive 2004/24/EC.
1997: Ranitidine 1998: Domperidone 2000: Cimetidine
10 aesgp.eu
2002 2003 2004 2005 2006 2007 2008
Further EU enlargement and
consequent harmonisation
of rules for medicines in
European countries has been
a main recent development.
Patient empowerment has
also been a major trend in
healthcare in the past years.
2001: Levonorgestol, Triamcilonone 2002: Loratadine 2003: Omeprazole
G10 report
The High Level Group on
innovation and provision
of medicines, a European
Commission policy
initiative, publishes report
making significant policy
recommendations for non-
prescription medicines,
noting that no price control
is required for these
products.
Regulation 726/04, Title IV
A revision of the European marketing authorisation
procedures in 2004 gives non-prescription
medicines the possibility to use the centralised
procedure.
Directive 2004/24/EC
Legislation on herbal medicines, harmonising
definition of traditional herbal medicinal
products which could benefit from simplified
procedure and setting up a Committee on
Herbal Medicinal Products within the EMA.
Development of information policy -
European Commission funded AESGP
study and presents indications for self-
care (see page 21).
European Union enlargement
with ten new member states
50 Years AESGP 11
2009 2010 2011 2012 2013 2014
A policy initiative by AESGP
identifies key areas requiring
regulatory improvement in order
to support the development of the
self-care sector.
Reclassifications through the centralised procedure
2009: Orlistat , Pantoprazole 2013: Esomeprazole
Process on Corporate Responsibility
The European Commission launches
a 3-year policy initiative examining
Ethics and Transparency in the
pharmaceutical sector and Access to
medicines in Europe and Africa.
A dedicated multi-stakeholder project
group on non-prescription medicines
examines how to improve uptake of
medicines following reclassification to
non-prescription status.
AESGP Medical Devices Committee established
Addressing the growth of the self-care medical
devices sector and the introduction of new European
legislation on medical devices, AESGP sets up a
new Committee on self-care medical devices.
2004: Simvastatin 2005: Chloramphenicol
Agreement on
elements of
success
Facilitating
innovation
Early
stakeholder
involvement
Collaboration
and
engagement
Training and
education
Access to
information
How to
achieve good
governance
S e l f - c a r e : T h e f i r s t c h o i c e i n h e a l t h c a r e
7 avenue de Tervuren, 1040 Brussels, Belgium | Tel: + 32 2 735 51 30 | Fax: + 32 2 735 52 22 | info@aesgp.eu | www.aesgp.eu
12 aesgp.eu
Mission
The mission of AESGP is to ensure a sustainable positive development
of the self-care industry.
AESGP is working to achieve this by focusing on the following strategic objectives:
To ensure that self-care plays an increasingly valuable role in healthcare as a positive
and cost-effective contributor to the health and well-being of Europes citizens.
To ensure that consumers can be well informed on the availability of self-care products,
e.g. through advertising, presentation in pharmacies and through the development of
brands which they can trust and rely on.
To ensure recognition of the self-care industrys role as a reliable and trustworthy
provider of self-care solutions.
To achieve the adoption and implementation of a balanced and proportionate
regulatory and economic framework that facilitates innovation and rapid market access
for the widest range of self-care products in a consistent way across Europe.
To promote a competitive environment for the self-care market, supporting free pricing
by manufacturers for self-care products.
Policy recommendations presented in the AESGP publication: Self-Care: A Winning Solution
50 Years AESGP 13
A balanced benefit-risk assessment for
Marketing Authorisations
Evaluation procedures for non-prescription
medicines should take into consideration
the benefits of the use of products in the
practice of responsible self-care and not
focus exclusively on risks regardless of
whether or not these can be mitigated. A
balanced assessment can better serve the
interests of European citizens.
Facilitating the switch process for
appropriate ingredients
A systematic, comprehensive approach
to the reclassification of prescription
medicines and active ingredients that takes
into account the specific characteristics of
self-care products and the need to reward
investments is necessary to reduce the
inequalities between European citizens
in different member states and to take full
advantage of the potential of self-care.
Detailed product information
Citizens should have access to detailed
product information and instructions of use
in order to be able to use self-care in a safe
and responsible manner and thus improve
their health.
Comprehensive advertising
Consumers should be able to get
information through the communication
channels they prefer without restrictions,
be it in specialised written press, public
displays, TV or digital media. Clear self-
governing principles should be agreed in all
EU member states.
Better visibility
Increased visibility of products at the
point of sale should be assured to give
consumers the time to make an informed
and responsible choice concerning their
self-care treatment.
Consistent branding
Consistent branding using traditional,
wellknown brands should be encouraged in
order to help individuals navigate through
available products.
Competitive pricing
Industry should be allowed to engage in
competitive pricing in order for the self-
care market to function without distortions
and for individuals to be able to reap all the
benefits of a free market.
Rigorous research on the role of self-care
Stakeholders and institutions (e.g. the
European Commission) involved in
research should commission research on
the role, importance and efficiency of self-
care in Europes healthcare systems in
order to define appropriate regulation and
incentives.
Challenge for the future - AESGP Policy Recommendations
Policy recommendations presented in the AESGP publication: Self-Care: A Winning Solution
14 aesgp.eu
AESGP Members
AESGP is the voice of more than 2000 companies operating in the consumer healthcare
sector in Europe, affiliated with AESGP directly or indirectly through the national
associations. The AESGP constituency includes the main multinational companies as well
as the European SMEs of the sector.
Austria
Denmark
The Danish
Association of the
Pharmaceutical Industry
Germany
Ireland
Netherlands
ASSOSALUTE
Associazione nazionale farmaci di automedicazione
Belgium
Czech Republic
France
Hungary
Lithuania
NEPROFARM
Neprofarm
NEPROFARM
Belgium
Croatia
Finland
Greece
Italy
National associations
50 Years AESGP 15
Portugal
Sweden
Poland
Spain
United-Kingdom Turkey
GSK Boehringer Ingelheim
Merz Merck
PGT Pfizer
Farbe/colour:
PANTONE 288 CV
Reckitt Benckiser Sanofi
Norway
Slovenia
Switzerland
Bayer
Johnson-&-Johnson
Novartis
International companies (with a Board seat)
16 aesgp.eu
How AESGP works
AESGP brings the consumer healthcare industry into contact with policy makers and other
stakeholders at the European level. Support on the national level is also provided when
requested by national organisations.
The Association is regularly consulted on healthcare issues and in particular pharmaceutical,
food and health policy matters in Europe. AESGP comments and input in various
consultations and policy initiatives provide a clear view of the self-care sectors positions to
European Union institutions and contribute to the European health dialogue.
The AESGP Board is composed of representatives of member associations and international
companies and decides on the overall positioning of the association and important policy
issues.
Member
associations
Experts
from member
associations
Commitees
Board
Member
companies
Experts
from member
companies
50 Years AESGP 17
AESGP Committees are the operational
branches of the association.
Based on the strategic guidance provided
by the Board, AESGP Committees follow
closely and in depth developments in their
respective areas and implement policies of
the association.
The Committees also function as platforms
for sharing information on national practices
between AESGP members, with a view to
studying and promoting best practices in
the self-care sector in Europe.
All work is coordinated by the AESGP
offices in Brussels.
Worldwide
AESGP represents its members in the World
Self-Medication Industry (WSMI).
As a Non-Governmental Organisation (NGO)
in official relations with the World Health
Organization, WSMI contributes to WHOs
Public Health goals through specialised
expertise. WSMI also represents the
industry in other international organisations,
such as ICH, WIPO, Codex Alimentarius
and internationl health professionals
organisations.
In close collaboration with WSMI, AESGP
informs its members of all relevant
developments taking place on a global
level with a potential impact on Europe.
Commitees
Economic
Affairs/PR
Herbal
medicines
Regulatory
Affairs
Food
Supplements
Medical
devices
18 aesgp.eu
Stakeholder collaboration
Over the past 50 years, AESGP has worked together with representative bodies of health
professionals, patients and consumers in order to promote the practice of responsible self-
care.
AESGP worked together with the European umbrella
organisation of medical doctors, the Standing Committee of
European Doctors (CPME), and the European organisations of
medical specialists (UEMS) and general practitioners (UEMO)
to develop an information document on self-medication in an
initiative supported by the European Commission.
http://www.aesgp.eu/self-care
Working with other industry associations
AESGP also regularly works together with European umbrella associations representing
other sections of (the pharmaceutical) industry to address jointly common issues faced in
Europe.
AESGP is member of numerous institutional stakeholder groups
Health Policy Forum, eHealth Stakeholder Group, Process on
Corporate Responsibility, Advisory Forum on the Food Chain and
Animal and Plant Health , Working Groups on medical devices
European
Commission
50 Years AESGP 19
AESGP and PGEU, the representative body of
community pharmacists in Europe, expressed
their commitment to cooperate to promote the
practice of selfcare in a Charter of Collaboration
signed in 1993 and renewed in 2004 and 2012.
The Charter acknowledges the key role of
pharmacists in helping to ensure safe and
effective use of non-prescription medicines.
It also points to the role of the European self-
medication industry in ensuring that innovative,
safe products of high quality reach the
European consumers.
Key commitments by the two associations
include developing pharmacies into health
centres within their communities, improving
citizens knowledge of health care products,
and communicating the benefits of self- care
to regulators
AESGP also agreed with the European
Association of Pharmaceutical Full-line
Wholesalers (GIRP) to cooperate in the
active presentation of non-prescription
medicines in pharmacies and on the
appropriate space/category management,
taking into account and respecting national
particularities and differences.
Both organisations recognise the importance
of supporting the training of pharmacists
and their staff in their role to communicate
the benefits of non-prescription medicines;
on the exchange of information on the
supply and purchase of non-prescription
medicines in the marketplace; and the need
to ensure the most efficient way to supply
non-prescription medicines to pharmacies.
1993
2004
2012
EMA Interested Party
EFSA Stakeholder Platform
EUnetHTA Stakeholder Platform
20 aesgp.eu
Publications
E
c
o
n
o
m
i
c
a
n
d
L
e
g
a
l
F
r
a
m
e
w
o
r
k
f
o
r
N
o
n
-
P
r
e
s
c
r
i
p
t
i
o
n
M
e
d
i
c
i
n
e
s
Economic and
Legal Framework for
Non-Prescription Medicines
aesgp.eu
Association Europenne des Spcialits
Pharmaceutiques Grand Public
Association of the European
Self-Medication Industry
Europischer Verband der
Arzneimittel-Hersteller
Self-care : The rst choice in health care
2013
Economic and Legal
Framework for non-
prescription medicines
2013 - 18th Edition (648 pages)
Legal and Regulatory
Framework for Herbal
Medicines
2012 - 3rd Edition (354 pages)
Legal and Regulatory
Framework for Food
Supplements
2012 - 2nd Edition (401 pages)
The AESGP framework studies provide information on regulatory and market access
provisions applicable to non-prescription medicines, herbal medicines and food
supplements. Updated in collaboration mainly with WSMI and AESGP members, the studies
are reference points for the sector and are often cited in various activities and publications
by health authorities and other stakeholders.
1993 Self-Medication and the Pharmacist
1993 Developing Self-Medication in Central
and Eastern Europe
1994 The Individual and Health Care:
Added Value through Self-Medication
1996 The Value of the same Trademark for
medicines with a different Legal Status
1997 CPME/AESGP Brochure on Self-
Medication, supported by the European
Commission
1997 The Visibility of Self-Medication Products
in the Changing Pharmacy Environment
1998 Study on herbal medicinal products
carried out by AESGP on behalf of the
European Commission in English/German
1998 Medicines for Europe - A practical guide
for the development, registration and
marketing of medicinal products in the
European Union
1998 Encouraging self-medication can reduce
the healthcare cost burden: An Economic
Analysis
1998 Improving Visibility of Self-Medication in
Pharmacies
1999 Deregulation 2001-The Future of
Medicine Regulation in Europe

2002 Common statement and Report of the
PGEU-AESGP Workshop How
appropriate presentation of non-
prescription medicines enhances the
role of the pharmacist
2002 Final report of the AESGP research
project Development of an information
policy for medicinal products
2004 The Economic and Public Health value of
Self-medication
2008 Smart Regulation 2015
2012 Self-Care: A Winning Solution
Annual reports highlighting AESGP
activities and conference repots
presenting meeting proceedings
http://www.aesgp.eu/publications
50 Years AESGP 21
Acne
Allergic conjunctivitis
Cold
Cold sores
Constipation
Cough
Diarrhoea
Emergency contraception
Erectile dysfunction
Fever
Flu prevention
Flu treatment
Haemorrhoids
Hayfever prevention
Arthritic pain
Caries prevention
Cholesterol lowering/lipid control
Dermatitis/eczema
Hayfever treatment
Male pattern baldness
Neural tube defect prevention
Bacterial conjunctivitis
Cystitis
Exercise-induced angina
Helminth infections
Lower urinary tract infection
Vaginal thrush
Anxiety
Asthma
Benign prostatic hypertrophy
Chronic insomnia
Depression (mild to moderate)
Diabetes (prevention of
complications and treatment
with oral agents)
Heart disease prevention
Herpes genitalis
Irritable bowel syndrome
Inflammatory bowel disease
Gout
Hypertension
Incontinence
Headache
Indigestion/heartburn
Insomnia (temporary)
Mild/moderate pain
Minor cuts and bruises
Mouth ulcers
Nausia from known causes
Smoking cessation
Sore throat
Symptoms of PMS
Topical bacterial infections
Weight management
Self-diagnosis &
self-management
Recurrent/semi-
chronic condition
Short-term use/
acute condition
Long term use/
chronic condition
Doctor consultation & other health professional advice &
patient self-management (with/without medical advice)
Indications for self-care. From the European Commission funded project conducted by AESGP:
Information policy for non-prescription medicines (2002). The project examined different indications
for self-care and presented the concept of collaborative care.
Malaria prevention
Menopause syndrome
Migraine
Obesity
Oral contraception
Osteoporosis prophylaxis
Psoriasis (mild)
Rheumatism
Venous leg ulcers
22 aesgp.eu
The significant economic value of self-medication was examined in different AESGP
publications.
In 2004, an economic analysis identified the significant savings potential of self-medication
by estimating the cost reductions of switching treatment from professional care to self-
medication.
The publication Self-Care: A Winning Solution also addressed the public health and
economic benefits of self-care, providing an overview of the outcomes of economic
analyses at national level.
Each year, AESGP publishes online an overview of sales figures in Europe. The market data
are provided mostly by national member associations and collected in the context of the
preparation of the Economic and Legal Framework study for non prescription medicines.
http://www.aesgp.eu/facts-figures/market-data (open access)
Market data
50 Years AESGP 23
Ingredients
An online database of ingredients with
non-prescription status in European and
non-European countries is maintained by
AESGP.
The database allows users to search
ingredients by name in order to find their
classification status in one or all available
countries, while a search by parameter
function allows users to get information on
the classification status based of ingredients
based on ATC levels 1 or 2, the year of
switch, or by country.
Information in the database comes
mainly from WSMI and AESGP member
Ingredients Directory
2014
http://www.aesgp.eu/facts-figures/market-data (open access)
Data Bank data.aesgp.eu
AESGP Data Bank
The AESGP Data Bank is the online
database launched in June 2014. It includes
information previously found in the AESGP
studies Economic and Legal Framework
for non-prescription medicines and Legal
and Regulatory Framework for Herbal
Medicines.
Providing a variety of options to users and
flexibility in the presentation of results, a key
objective of the new database is to improve
further the understanding of circumstances
under which the practice of responsible
self-care can be further encouraged and
supported.
http://data.aesgp.eu (for registered users only)
http://www.aesgp.eu/facts-figures/data-bank (registration information, open access)
associations and is updated regularly by
AESGP. The outcomes of the March 2014
update are also presented in the publication
AESGP Ingredients Directory.
24 aesgp.eu
Dublin
April 2628, 1978
June 57, 2002
Paris
November 1963 (foundation)
March 1965
December 2, 1966
June 1315, 1984
Annual Meetings
Brussels
October 30, 1967
October 3031, 1972
June 2729, 1990
Rome
November 2122, 1969
June 710, 1989 (together with the 9th
General Assembly of WFPMM)
June 810, 2011
June 69, 2001
London
Nov. 28 Dec. 1, 1971 (together with
the 1st WFPMM General Assembly)
February 2527, 1976
June 1416, 1994
June 35, 2014 (together with the 18th
WSMI General Assembly of WSMI)
Madrid
May 24, 1979
June 24, 2004
Amsterdam
April 2325, 1980
June 911, 1993
Funchal (Madeira)
May 2023, 1981
Cannes
October 2830, 1973
June 24, 1991
June 46, 2003
Barcelona
June 2426, 1992
Lisbon
June 710, 1995
June 57, 2013
Nice
June 68, 2012
50 Years AESGP 25
Lausanne
October 2425, 1968
Rome
November 2122, 1969
June 710, 1989 (together with the 9th
General Assembly of WFPMM)
June 810, 2011
June 69, 2001
Baden-Baden
October 1114, 1970
Vienna
October 34, 1974
May 2022, 1987
June 35, 2009
Geneva
March 2023, 1977 (together with
the 4th WFPMM General Assembly)
June 1517, 1988
June 13, 2005 (together with the
15th WSMI General Assembly)
Amsterdam
April 2325, 1980
June 911, 1993
Athens
May 1214, 1982
May 2023, 1998
June 79, 2006
Stockholm
June 810, 1983
June 1113, 2008
Munich
May 2931, 1985
Copenhagen
June 1113, 1986
Istanbul
May 29June 1, 1996
Budapest
June 1821, 1997
Berlin
June 912, 1999 (together with the
13th WSMI General Assembly)
Helsinki
May 1720, 2000
Warsaw
43. June 46, 2007
Dubrovnik
June 912, 2010
Munich
May 29-31, 1985
26 aesgp.eu
Jean Sall | France
Daniel Callewaert | Belgium
Hans W. Bach | Germany
Frederick G. Razzell | UK
Pierre Teisseire | France
D.N.A. McLure | UK
P. Giorgio Aquino | Italy
Anthony J. Jamison | UK
Antony B. Claasen | Netherlands
Jos-Antonio Perez-Espana | Spain
John R. Markley | UK
Heinz Schmidgall | Switzerland
Roberto Montanari | Italy
Berndt van Till | Netherlands
Hugues Lanrezac | France
Gerhard Stummerer | Austria
Alessandro Banchi | Italy
Albert Esteve | Spain
Hans van Zoonen | Switzerland
Hans Regenauer | Germany
Presidents and Directors General
Presidents
1 9631 969
1 9691 972
1 9721 974
1 9741 975
1 9751 978
1 9781 980
1 9801 981
1 981 1 984
1 9841 986
1 9861 988
1 9881 989
1 9891 992
1 9921 994
1 9941 996
1 9961 998
19982000
20002002
20022005
20052009
Since 2009
1 9641 968
1 9681 978
1 9791 988
Since 1988
Directors General
Beverley Landrey
Pierre A. Visseur
Werner Sedlag
Hubertus Cranz
Logo 1964 - 1989
Logo 1989 - 1999 Logo 1999 - 2005 Logo introduced in 2005
50 Years AESGP 27
Directors General
AESGP Euro OTC News
Each month, AESGP publishes the AESGP
Euro OTC News.
The newsletter is distributed to the AESGP
constituency with the purpose of informing
members about the latest developments
on non-prescription medicines, food
supplements and self-care medical devices.
The newsletter provides an overview of
issues circulated in the course of the month
before to Committee members. It also
provides all the latest information on AESGP
activities as well as news from members.
AESGP launched the first issue of its newsletter in 1990.
Today, after more than 250 issues circulated in paper and electronic version, the AESGP
Euro OTC News continues to serve as an informative and useful communication tool and is
part of the AESGP service to its members.
Self Care:
The rst choice in healthcare
The Association of the European Self-Medication Industry
is the representative body of the manufacturers
of non-prescription medicines, food supplements
and self-care medical devices in Europe.
AESGP
7 avenue de Tervuren
B-1040 Brussels, Belgium
Tel: +32 2 735 51 30
Fax: +32 2 735 52 22
E-mail: info@aesgp.eu
aesgp.eu